- Home
- NVAX vs CMPR Comparison
NVAX vs CMPR Comparison
Compare NVAX & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- CMPR
- Stock Information
- Founded
- NVAX 1987
- CMPR 1994
- Country
- NVAX United States
- CMPR Ireland
- Employees
- NVAX N/A
- CMPR N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CMPR Publishing
- Sector
- NVAX Health Care
- CMPR Consumer Discretionary
- Exchange
- NVAX Nasdaq
- CMPR Nasdaq
- Market Cap
- NVAX 1.3B
- CMPR 1.2B
- IPO Year
- NVAX 1995
- CMPR N/A
- Fundamental
- Price
- NVAX $7.84
- CMPR $62.66
- Analyst Decision
- NVAX Hold
- CMPR Strong Buy
- Analyst Count
- NVAX 6
- CMPR 2
- Target Price
- NVAX $15.00
- CMPR $72.00
- AVG Volume (30 Days)
- NVAX 8.6M
- CMPR 275.4K
- Earning Date
- NVAX 08-06-2025
- CMPR 07-29-2025
- Dividend Yield
- NVAX N/A
- CMPR N/A
- EPS Growth
- NVAX N/A
- CMPR N/A
- EPS
- NVAX 2.54
- CMPR 0.58
- Revenue
- NVAX $1,078,718,000.00
- CMPR $3,403,079,000.00
- Revenue This Year
- NVAX $52.02
- CMPR $4.43
- Revenue Next Year
- NVAX N/A
- CMPR $3.29
- P/E Ratio
- NVAX $3.08
- CMPR $108.60
- Revenue Growth
- NVAX 9.22
- CMPR 3.38
- 52 Week Low
- NVAX $5.01
- CMPR $35.21
- 52 Week High
- NVAX $15.22
- CMPR $102.22
- Technical
- Relative Strength Index (RSI)
- NVAX 48.26
- CMPR 71.54
- Support Level
- NVAX $7.57
- CMPR $58.72
- Resistance Level
- NVAX $10.64
- CMPR $61.13
- Average True Range (ATR)
- NVAX 0.72
- CMPR 2.28
- MACD
- NVAX -0.07
- CMPR 0.20
- Stochastic Oscillator
- NVAX 29.47
- CMPR 89.04
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.